Pharma Stock Soars 13% After Company Considers Its First-Ever Share Buyback

Synopsis:-Shares surged nearly 13% after the board scheduled a March 12, 2026, meeting to consider a share buyback of equity shares with a ₹2 face value. The stock traded around ₹187, with a ₹1,250 crore market cap, while investors watch the outcome of the company’s first potential buyback announcement.

The shares of the prominent pharma company jumped up to 13 percent in today’s trading session after the company announced that its board of directors is may consider and approve a buyback proposal.

With a market capitalization of Rs 1,250.85 crore, the shares of Jagsonpal Pharmaceuticals Ltd were trading at Rs 187.00 per share, increasing around 10.19 percent as compared to the previous closing price of Rs 169.70 apiece.

Buyback

Shares of Jagsonpal Pharmaceutical Limited have seen positive momentum after the company announced that its board will meet on March 12, 2026, to consider a proposal for a share buyback of fully paid-up equity shares with a face value of  Rs 2 each. If approved, this would mark the company’s first-ever buyback, signalling potential confidence in its financial position and capital allocation strategy.

Meanwhile, the company has previously undertaken shareholder-friendly actions. In July 2004, it issued bonus shares in a 3:1 ratio, rewarding investors with additional shares. More recently, in January 2025, it implemented a stock split, reducing the face value from  Rs 5 to  Rs 2. These steps indicate a consistent effort to improve liquidity and enhance shareholder value over time.

Financial Highlights

The company reported a weak financial performance in Q3FY26, with revenue slightly declining to  Rs 73 crore from  Rs 74 crore in the same quarter last year. More notably, profitability saw significant pressure as net profit dropped sharply by 66% to  Rs 11 crore, indicating margin challenges and possible cost or operational pressures.

Over the past year, operating performance showed some volatility but improved overall. Operating profit stood at  Rs 16 crore in Dec 2024, declined to  Rs 9 crore in Mar 2025, and then recovered to  Rs 14 crore in Jun 2025. It further strengthened to  Rs 16 crore by Sep and Dec 2025. Meanwhile, OPM improved from 21% to a stable 22%, indicating better cost efficiency.

Jagsonpal Pharmaceutical Limited reported steady operational performance, with Q3 revenue reaching  Rs 729 million while nine-month revenue grew 6% year-on-year to  Rs 2,230 million. EBITDA margin remained healthy at 22.7%. Net profit rose to  Rs 125 million in Q3, supported by strong execution, while cash balance improved to  Rs 1,757 million, reflecting solid financial discipline.

Ace investor Mukul Agrawal holds 11,57,557 equity shares, which is equivalent to 1.73 percent, in the company as of December 2025. Jagsonpal Pharmaceutical Limited is an Indian pharmaceutical company engaged in developing, manufacturing, and marketing a wide range of formulations. The company focuses on therapeutic areas such as gynecology, dermatology, pain management, and nutrition. Over the years, it has built a strong presence in domestic markets through an expanding product portfolio.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Soars 13% After Company Considers Its First-Ever Share Buyback appeared first on Trade Brains.